Tag: Eisai

Bristol-Myers Squibb starts research collaboration with Eisai

bristol-myers squibb
Bristol-Myers Squibb, Eisai and H3 Biomedicine announced research collaboration focused on H3’s RNA splicing platform.

Drug candidate from Eisai-UCL collaboration to enter Phase I clinical trials

Eisai announced that the first drug candidate from their drug discovery collaboration with University College London is to enter Phase I clinical trials for Alzheimer's disease in early 2019.

Eisai to create new drug discovery center in USA

Eisai announced it will launch the Eisai Center for Genetics Guided Dementia Discovery, which will harness the power of human genetics to develop next-generation medicines for Alzheimer's disease (AD) and other dementias.

Eisai will develop a new treatment for tuberculosis aided by US scientists

Japanese pharmaceutical company Eisai entered into a joint research agreement with the Broad Institute, Mycobacteria Research Laboratories at Colorado State University and the University of Chicago.

Eisai and Nichi-Iko Pharmaceutical entered a strategic alliance agreement

Eisai (Tokyo, Japan) and Nichi-Iko Pharmaceutical (Toyama, Japan) entered into a strategic alliance agreement as well as a share transfer agreement for a capital and business alliance.

Eisai and MSD will jointly develop and commercialize a thyroid cancer therapy

Eisai Co., Ltd. and MSD agreed upon a strategic collaboration for the worldwide co-development and co-commercialization of LENVIMA (lenvatinib mesylate), an orally available tyrosine kinase inhibitor discovered by Eisai.

Japanese company Eisai expands its capacity in China

Eisai Co. Ltd., announced today that its Chinese subsidiary, Eisai China Inc. has completed construction of a new oral solid dose production facility